How I manage anemia related to myelofibrosis and its treatment regimens

Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by mutations (most frequently in JAK2, CALR, or MPL), burdensome symptoms, splenomegaly, cytopenia, and shortened life expectancy. In addition to other clinical manifestations, patients with MF often develop anemia, which can either b...

Descripción completa

Detalles Bibliográficos
Autor principal: Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998582/
https://www.ncbi.nlm.nih.gov/pubmed/36786879
http://dx.doi.org/10.1007/s00277-023-05126-4
_version_ 1784903497150365696
author Verstovsek, Srdan
author_facet Verstovsek, Srdan
author_sort Verstovsek, Srdan
collection PubMed
description Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by mutations (most frequently in JAK2, CALR, or MPL), burdensome symptoms, splenomegaly, cytopenia, and shortened life expectancy. In addition to other clinical manifestations, patients with MF often develop anemia, which can either be directly related to MF pathogenesis or a result of MF treatment with Janus kinase (JAK) inhibitors, such as ruxolitinib and fedratinib. Although symptoms and clinical manifestations can be similar between the 2 anemia types, only MF-related anemia is prognostic of reduced survival. In this review, I detail treatment and patient management approaches for both types of anemia presentations and provide recommendations for the treatment of MF in the presence of anemia.
format Online
Article
Text
id pubmed-9998582
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99985822023-03-11 How I manage anemia related to myelofibrosis and its treatment regimens Verstovsek, Srdan Ann Hematol Review Article Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by mutations (most frequently in JAK2, CALR, or MPL), burdensome symptoms, splenomegaly, cytopenia, and shortened life expectancy. In addition to other clinical manifestations, patients with MF often develop anemia, which can either be directly related to MF pathogenesis or a result of MF treatment with Janus kinase (JAK) inhibitors, such as ruxolitinib and fedratinib. Although symptoms and clinical manifestations can be similar between the 2 anemia types, only MF-related anemia is prognostic of reduced survival. In this review, I detail treatment and patient management approaches for both types of anemia presentations and provide recommendations for the treatment of MF in the presence of anemia. Springer Berlin Heidelberg 2023-02-14 2023 /pmc/articles/PMC9998582/ /pubmed/36786879 http://dx.doi.org/10.1007/s00277-023-05126-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Verstovsek, Srdan
How I manage anemia related to myelofibrosis and its treatment regimens
title How I manage anemia related to myelofibrosis and its treatment regimens
title_full How I manage anemia related to myelofibrosis and its treatment regimens
title_fullStr How I manage anemia related to myelofibrosis and its treatment regimens
title_full_unstemmed How I manage anemia related to myelofibrosis and its treatment regimens
title_short How I manage anemia related to myelofibrosis and its treatment regimens
title_sort how i manage anemia related to myelofibrosis and its treatment regimens
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998582/
https://www.ncbi.nlm.nih.gov/pubmed/36786879
http://dx.doi.org/10.1007/s00277-023-05126-4
work_keys_str_mv AT verstovseksrdan howimanageanemiarelatedtomyelofibrosisanditstreatmentregimens

Ejemplares similares